Prospects Oncology Fund
FACIT’s Prospects Fund is designed to support early stage proof-of-concept (POC) studies within Ontario academic institutions and start-ups that fit with FACIT’s Investment Strategy and have the potential to act as deal flow for the IPDC Fund. Awarded grants typically range between $50,000 and $200,000.
Funding is governed by a research contract which grants certain rights to FACIT. FACIT receives no financial consideration on Prospects grants under $100,000. On grants of $100,000 or more, FACIT receives an option to make an investment at the IPDC level and act as the agent for commercialization. If the option is exercised, funding received from the Prospects grant will be credited towards FACIT's IPDC investment.
How to apply:
The Prospects Fund is accepting pre-submission forms twice yearly on the following dates:
- March 31
- September 30
The pre-submission form can be downloaded here.
Late applications will not be considered.
Selected applicants will then be invited to prepare a Prospects funding application which is subject to due diligence by FACIT.
Select Prospects Funded Projects
Prospects Fund (Other)
Evaluation of survival benefit and preclinical proof of concept of a novel ganglioside-based cancer vaccine.
Evaluation of novel potassium channel antagonists, initially developed for neurodegenerative disorders, as cancer therapeutics.
The platform intends to make it easier for stakeholders to form public and private data sharing networks, and systematize genotype-phenotype associations, patient matching, and recruitment through
Development of multi-spectral X-ray imagers that improve the quality and accuracy of chest X-rays, while helping to reduce the demand for CT cancer diagnostics.